Bioabsorbable spacers enable high-dose pancreatic proton therapy, but severe adverse events remain
In 13 patients receiving spacer-assisted pancreatic proton therapy, 30.8% had grade 3 events and two-year local control was 38.2%.
In 13 patients receiving spacer-assisted pancreatic proton therapy, 30.8% had grade 3 events and two-year local control was 38.2%.
Among 12 patients, pancreatic SBRT with 30 Gy elective nodal irradiation produced one acute dose-limiting event and three grade 3 cholangitis events.
In 473 pancreatic cancer patients, SBRT achieved 82% one-year local control, with higher biologically effective dose associated with better response.
Among 63,261 nonsurgical pancreatic cancer patients, chemotherapy plus RT was associated with longer survival, although the apparent benefit diminished over time.
In 50 pancreatic SBRT fractions, expert recontouring identified duodenal dose-limit exceedances in two patients despite largely preserved target coverage.
In PACK, one-year survival reached 78% after carbon-ion chemoradiotherapy, but progression remained frequent and no randomized comparator was available.
Two patients with tumor-induced acute pancreatitis experienced pain relief and declining pancreatic enzymes after palliative radiotherapy of 8 Gy/2 or 20 Gy/5.
After 50 Gy in five fractions, local progression was 15% at one year, while distant progression remained the dominant failure pattern.
Higher tumor SMAD4 was associated with better disease-free survival and lower distant metastatic risk after resection and adjuvant chemoradiotherapy.
In two PDAC cell lines, measured proton RBE remained near 1.0 through the Bragg peak but rose as high as 6.1 distally.
SBRT can provide high local control in selected oligometastatic pancreatic cancer, but randomized survival evidence and patient-selection criteria remain limited.
ASTRO expands radiation therapy recommendations across locally advanced, recurrent and oligometastatic pancreatic cancer, with new guidance on dose escalation and adaptation.
Repeated end-expiratory breath-hold CBCT achieved boundary sharpness statistically equivalent to daily CT in 10 pancreatic SBRT patients.
Two- to five-millimetre gastrointestinal margins usually limited delivered dose increases but frequently failed to encompass interfraction organ motion.
ATR inhibition increased radiation-induced cell killing and inflammatory signalling in KRAS wild-type pancreatic cancer cells, with weaker immunogenic effects in KRAS-mutated cells.